AAAAAA
Results: 26-50/73
Authors:
Grulich, AE
Wan, XN
Law, MG
Milliken, ST
Lewis, CR
Garsia, RJ
Gold, J
Finlayson, RJ
Cooper, DA
Kaldor, JM
Citation: Ae. Grulich et al., B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS, AIDS, 14(2), 2000, pp. 133-140
Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection
Authors:
Law, MG
Li, YM
McDonald, AM
Cooper, DA
Kaldor, JM
Citation: Mg. Law et al., Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection, AIDS, 14(2), 2000, pp. 197-201
Authors:
Kaufmann, GR
Zaunders, JJ
Cunningham, P
Kelleher, AD
Grey, P
Smith, D
Carr, A
Cooper, DA
Citation: Gr. Kaufmann et al., Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection, AIDS, 14(17), 2000, pp. 2643-2651
Authors:
Miller, J
Carr, A
Smith, D
Emery, S
Law, MG
Grey, P
Cooper, DA
Citation: J. Miller et al., Lipodystrophy following antiretroviral therapy of primary HIV infection, AIDS, 14(15), 2000, pp. 2406-2407
Authors:
Cunningham, PH
Smith, DG
Satchell, C
Cooper, DA
Brew, B
Citation: Ph. Cunningham et al., Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid, AIDS, 14(13), 2000, pp. 1949-1954
Authors:
Kroon, EDMB
Ungsedhapand, C
Ruxrungtham, K
Chuenyam, M
Ubolyam, S
Newell, ME
van Leeuwen, R
Kunanusont, C
Buranapraditkul, S
Sirivichayakul, S
Lange, JMA
Cooper, DA
Phanuphak, P
Citation: Edmb. Kroon et al., A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001), AIDS, 14(10), 2000, pp. 1349-1356
Authors:
Ruxrungtham, K
Kroon, EDMB
Ungsedhapand, C
Teeratakulpisarn, S
Ubolyam, S
Buranapraditkun, S
van Leeuwen, R
Weverling, GJ
Kunanusont, C
Lange, JMA
Cooper, DA
Phanuphak, P
Citation: K. Ruxrungtham et al., A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients, AIDS, 14(10), 2000, pp. 1375-1382
Authors:
Carr, A
Cooper, DA
Citation: A. Carr et Da. Cooper, Adverse effects of antiretroviral therapy, LANCET, 356(9239), 2000, pp. 1423-1430
Authors:
Carpenter, CCJ
Cooper, DA
Fischl, MA
Gatell, JM
Gazzard, BG
Hammer, SM
Hirsch, MS
Jacobsen, DM
Katzenstein, DA
Montaner, JSG
Richman, DD
Saag, MS
Schechter, M
Schooley, RT
Vella, S
Yeni, PG
Volberding, PA
Citation: Ccj. Carpenter et al., Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel, J AM MED A, 283(3), 2000, pp. 381-390
Authors:
Tokita, H
Kaufmann, GR
Matsubayashi, M
Okuda, I
Tanaka, T
Harda, H
Mukaide, M
Suzuki, K
Cooper, DA
Citation: H. Tokita et al., Hepatitis C virus core mutations reduce the sensitivity of a fluorescence enzyme immunoassay, J CLIN MICR, 38(9), 2000, pp. 3450-3452
Authors:
Cooper, DA
Curran-Celentano, J
Ciulla, TA
Hammond, BR
Danis, RB
Pratt, LM
Riccardi, KA
Filloon, TG
Citation: Da. Cooper et al., Olestra consumption is not associated with macular pigment optical densityin a cross-sectional volunteer sample in Indianapolis, J NUTR, 130(3), 2000, pp. 642-647
Authors:
Smith, DM
Berrey, MM
Robertson, M
Mehrotra, D
Markowitz, M
Perrin, L
Clumeck, N
Lazzarin, A
Burckhardt, B
Weber, R
Corey, L
Cooper, DA
Citation: Dm. Smith et al., Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection, J INFEC DIS, 182(3), 2000, pp. 950-954
Authors:
Emery, S
Capra, WB
Cooper, DA
Mitsuyasu, RT
Kovacs, JA
Vig, P
Smolskis, M
Saravolatz, LD
Lane, HC
Fyfe, GA
Curtin, PT
Citation: S. Emery et al., Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease, J INFEC DIS, 182(2), 2000, pp. 428-434
Authors:
Vanhems, P
Hirschel, B
Phillips, AN
Cooper, DA
Vizzard, J
Brassard, J
Perrin, L
Citation: P. Vanhems et al., Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS, J INFEC DIS, 182(1), 2000, pp. 334-337
Authors:
Zaunders, JJ
Cunningham, PH
Kaufmann, GR
Cooper, DA
Citation: Jj. Zaunders et al., Questions about results reported with potent antiretroviral therapy for human immunodeficiency virus type 1 infection - Reply, J INFEC DIS, 181(4), 2000, pp. 1519-1520
Authors:
Carr, A
Cooper, DA
Citation: A. Carr et Da. Cooper, Primary HIV infection, IMMUNOL MED, 28, 2000, pp. 19-40
Authors:
Kaufmann, GR
Cunningham, P
Zaunders, J
Law, M
Vizzard, J
Carr, A
Cooper, DA
Citation: Gr. Kaufmann et al., Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4(+) T-lymphocyte counts in the first year of HIV-1 infection, J ACQ IMM D, 22(5), 1999, pp. 437-444
Authors:
Vanhems, P
Dassa, C
Lambert, J
Cooper, DA
Perrin, L
Vizzard, J
Hirschel, B
Kinloch-de Loes, S
Carr, A
Allard, R
Citation: P. Vanhems et al., Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection, J ACQ IMM D, 21(2), 1999, pp. 99-106
Authors:
Grulich, AE
Olsen, SJ
Luo, K
Hendry, O
Cunningham, P
Cooper, DA
Gao, SJ
Chang, Y
Moore, PS
Kaldor, JM
Citation: Ae. Grulich et al., Kaposi's sarcoma-associated herpesvirus: A sexually transmissible infection?, J ACQ IMM D, 20(4), 1999, pp. 387-393
Authors:
Kaufmann, GR
Zaunders, J
Cooper, DA
Citation: Gr. Kaufmann et al., Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy, SEX TRANS I, 75(4), 1999, pp. 218-224
Authors:
Cooper, DA
Andreasson, K
Citation: Da. Cooper et K. Andreasson, Predictive NOx emission monitoring on board a passenger ferry, ATMOS ENVIR, 33(28), 1999, pp. 4637-4650
Authors:
Cooper, DA
Emery, S
Citation: Da. Cooper et S. Emery, Latent reservoirs of HIV infection: Flushing with IL-2?, NAT MED, 5(6), 1999, pp. 611-612
Authors:
Been-Tiktak, AMM
Boucher, CAB
Brun-Vezinet, F
Joly, V
Mulder, JW
Jost, J
Cooper, DA
Moroni, M
Gatell, JM
Staszewski, S
Colebunders, R
Stewart, GJ
Hawkins, DA
Johnson, MA
Parkin, JM
Kennedy, DH
Hoy, JF
Borleffs, JCC
Citation: Amm. Been-tiktak et al., Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial, INT J ANT A, 11(1), 1999, pp. 13-21
Authors:
Benson, EM
Clarkson, J
Law, M
Marshall, P
Kelleher, AD
Smith, DE
Patou, G
Stewart, GJ
Cooper, DA
Ffrench, RA
Citation: Em. Benson et al., Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals, AIDS RES H, 15(2), 1999, pp. 105-113
Authors:
Zaunders, JJ
Geczy, AF
Dyer, WB
McIntyre, LB
Cooley, MA
Ashton, LJ
Raynes-Greenow, CH
Learmont, J
Cooper, DA
Sullivan, JS
Citation: Jj. Zaunders et al., Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4(+) and CD8(+) T lymphocytes: Increased CD45RO(+)CD4(+) T lymphocytes and limited activation of CD8(+) T lymphocytes, AIDS RES H, 15(17), 1999, pp. 1519-1527